<DOC>
	<DOCNO>NCT02956629</DOCNO>
	<brief_summary>This nonrandomized , multi-site , open-label trial evaluate novel two-drug combination regimen ( MK-3682 450 mg + ruzasvir [ RZR ; MK-8408 ] 180 mg daily [ q.d . ] 12 week ) male female treatment-naïve ( TN ) treatment-experienced ( TE ) participants chronic hepatitis C virus ( HCV ) infection genotype ( GT ) GT1 , GT2 , GT3 , GT4 , GT5 , GT6 previously receive HCV direct-acting antiviral ( DAA ) therapy . Cirrhotic ( C ) non-cirrhotic ( NC ) participant without human immunodeficiency virus ( HIV ) co-infection enrol .</brief_summary>
	<brief_title>Efficacy Safety MK-3682 + Ruzasvir ( MK-8408 ) Treating Hepatitis C Virus Infection Genotypes 1-6 ( MK-3682-041 )</brief_title>
	<detailed_description>Any GT meet virologic futility criterion give option extend treatment MK-3682 + RZR 16 week ribavirin ( RBV ) add .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HCV RNA ( ≥10,000 IU/mL peripheral blood ) time screen document chronic HCV GT1 , GT2 , GT3 , GT4 , GT5 , GT6 ( evidence nontypeable mixed GT ) female reproductive potential , female reproductive potential agree avoid become pregnant two week prior Day 1 14 day last dose study drug via abstinence use two approve contraceptive C NC coinfected HIV , document HIV infection prior Day 1 , either use antiretroviral therapy ( ART ) wellcontrolled HIV stable ART ( least 4 week prior study entry ) evidence decompensated liver disease C ChildPugh Class B C , ChildTucottePugh score &gt; 6 coinfected hepatitis B virus ( hepatitis B surface antigen hepatitis B core antibody positive ) coinfected HIV recent ( within 6 month prior screen ) opportunistic infection history malignancy adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ within 5 year sign informed consent C evidence ( liver image within 6 month prior Day 1 ) hepatocellular carcinoma ( HCC ) evaluation HCC participate another investigational drug study within 30 day sign informed consent female pregnant breastfeeding expect conceive donate egg Day 1 6 month last dose study drug longer dictate local regulation , male subject expect donate sperm Day 1 14 day last dose study drug longer dictate local regulation , male whose female partner ( ) is/are pregnant breastfeeding clinically relevant alcohol drug abuse within 12 month screen follow condition : organ transplant cornea hair ; poor venous access ; history gastric surgery ; clinically significant cardiac abnormality/dysfunction ; major medical condition , opinion investigator , might interfere participation ; hospitalization within 3 month prior enrollment ; condition might require hospitalization ; condition require likely require chronic systemic administration corticosteroid , tumor necrosis factor ( TNF ) antagonists , immunosuppressant drug ; lifethreatening serious adverse event ( SAE ) screening ; hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>